Patents Assigned to Universite Paris-Saclay
  • Patent number: 11913073
    Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: February 27, 2024
    Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
  • Patent number: 11913074
    Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: February 27, 2024
    Assignees: PML Screening, LLC, The Université Paris-Saclay, The Assistance Publique—Hôpitaux de Paris (APHP), The Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
  • Publication number: 20230382991
    Abstract: An antagonist antibody, or an antigen binding fragment thereof, binds both to human and macaque LILRB1 and/or LILRB2, and has diagnostic and therapeutic uses.
    Type: Application
    Filed: October 12, 2021
    Publication date: November 30, 2023
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Benoit FAVIER, Sixtine COINDRE, Anne WIJKHUISEN, Stéphanie SIMON, Roger LE GRAND, Olivier LAMBOTTE
  • Patent number: 11830718
    Abstract: A spectroscopy device including: an electron source arranged to emit a flux of electrons towards a sample, a pulsed photon source emitting photon pulses towards the sample, at least one spectrometer for receiving a flux of electrons originating from the sample, at least one electron detector; and at least one deflector, between the electron source and the at least one electron detector, synchronized with the pulsed photon source to allow or prevent the passage of electrons emitted by the electron source, towards the electron detector.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: November 28, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SACLAY
    Inventors: Mathieu Kociak, Marcel Tence, Jean-Denis Blazit, Pabitra Das
  • Publication number: 20230304065
    Abstract: The present invention relates to a method for screening compounds for bactericidal activity using thermostable luciferase and based on a real-time bioluminescence measurement. The present invention further relates to a method for determining the sensitivity of a bacterial sample originating from a subject suffering from a bacterial infection to a group of known antibiotics and to a method for assessing the minimum inhibitory concentration (MIC) of a bactericidal compound.
    Type: Application
    Filed: August 2, 2021
    Publication date: September 28, 2023
    Applicants: Centre National de la Recherche Scientifique (CNRS), Universite Paris-Saclay
    Inventors: Dominique FOURMY, Satoko YOSHIZAWA, Marie EBEYER-MASOTTA, Jean-Luc PERNODET
  • Publication number: 20230285381
    Abstract: The present invention relates to compounds of formula (I); for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: April 6, 2023
    Publication date: September 14, 2023
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Publication number: 20230255603
    Abstract: A device for supplying an ultrasonic transducer including a power interface configured to provide an analog power signal, called supply signal, to the ultrasonic transducer, and further including a delta-sigma modulator configured to produce a delta-sigma modulator of a sinusoidal signal, called drive signal, and provide a digital signal, called control signal, to control said power interface. Also an ultrasonic device powered by such a supply device, an ultrasonic head including such ultrasonic devices and an ultrasonic system including such an ultrasonic head.
    Type: Application
    Filed: July 27, 2021
    Publication date: August 17, 2023
    Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE [
    Inventors: Ming ZHANG, Nicolas LLASER
  • Publication number: 20230255105
    Abstract: The present invention relates to compounds simultaneously having thermally activated delayed fluorescence (TADF), circularly polarised luminescence (CPL) and aggregation-induced emission enhancement (AIEE) properties. The invention also relates to the use of such compounds as a photocatalyst or as a dopant, in particular in the emitting layers of light-emitting diodes (OLEDs), as well as light-emitting devices or light-emitting diodes (OLEDs) comprising such compounds.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 10, 2023
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ PARIS-SACLAY, UNIVERSITÉ DE RENNES 1, ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE RENNES, INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE RENNES
    Inventors: Grégory Pieters, Ludovic Favereau, Laurelie Poulard, Max Coehlo, Lucas Frederic, Sitthichok Kasemthaveechok, Jeanne Crassous
  • Patent number: 11692033
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: July 4, 2023
    Assignees: Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Saclay
    Inventors: Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
  • Publication number: 20230203005
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Application
    Filed: March 6, 2023
    Publication date: June 29, 2023
    Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND
  • Patent number: 11684640
    Abstract: The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 27, 2023
    Assignees: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, UNIVERSITE PARIS-SACLAY, Insitut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)
    Inventors: Laurence Zitvogel, Bertrand Routy, Emmanuelle Le Chatelier
  • Publication number: 20230190925
    Abstract: The present invention relates to phage T5 capsids that are devoid of genomic DNA from the phage and exposing, on their surface, at least one fusion protein of interest.
    Type: Application
    Filed: September 18, 2020
    Publication date: June 22, 2023
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-SACLAY
    Inventors: Pascale BOULANGER, Emeline VERNHES, Nicolas DUCROT, Linda LARBI CHERIF, Karim BENIHOUD
  • Patent number: 11679148
    Abstract: The inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to a method of treating a subject suffering from a cancer comprising a step of administration simultaneously, separately or sequentially to said subject a therapeutically amount of i) a population of derived engineered fetal stem cells carrying cancer associated fetal neo-antigen and ii) a compound selected from a group which activates immune response, as a combined preparation.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: June 20, 2023
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, UNIVERSITÉ PARIS-SACLAY, UNIVERSITÉ PARIS CITÉ
    Inventors: Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli, Christophe Desterke
  • Publication number: 20230149405
    Abstract: A topical composition including erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the composition is topically administered. The composition may further include a penetration enhancer. The treated subject may be younger than three years old. Also, woven or non-woven fabric support including erlotinib and to dressings, patches, gloves and socks having the support useful in the treatment of a PPK.
    Type: Application
    Filed: April 7, 2021
    Publication date: May 18, 2023
    Applicants: LABORATOIRES C.T.R.S., INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), FONDATION IMAGINE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS-SACLAY
    Inventors: Christine BODEMER, Céline GRECO, Claude BOUCHEIX, Jean-Pascal CONDUZORGUES, Joel SCHLATTER, Salvatore CISTERNINO
  • Patent number: 11642320
    Abstract: The present invention relates to anti-inflammatory drug formulation. Especially, this invention relates to corticosteroid prodrug nanoparticle. In a first aspect, this invention relates to a nanoparticle comprising a therapeutic agent and a surface coating material. The invention also relates to a process of manufacturing at least one nanoparticle of invention. The invention also relates to pharmaceutical composition and pharmaceutical kits.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: May 9, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SACLAY
    Inventors: Elias Fattal, Nicolas Tsapis, Mathilde Lorscheider, Romain Canioni, Franceline Reynaud
  • Patent number: 11634405
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 25, 2023
    Assignees: UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad Alami, Olivier Provot, Abdallah Hamze, Ilhem Khelifi, Timothée Naret, Sébastien Apcher, Romain Darrigrand
  • Patent number: 11590232
    Abstract: A bioconjugate comprising at least one neuropeptide covalently bond to at least one hydrocarbon compound of squalene structure.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: February 28, 2023
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SACLAY
    Inventors: Patrick Couvreur, Jiao Feng, Sinda Lepetre-Mouelhi
  • Patent number: 11560436
    Abstract: The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D?D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also relates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D?D3 domain.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: January 24, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS-SACLAY
    Inventors: Petrus Lenting, Gabriel Ayme, Cecile Denis, Olivier Christophe
  • Patent number: 11551749
    Abstract: The present invention relates to a neuromimetic network comprising a set of neurons and a set of synapses, at least one neuron comprising a first stack of superimposed layers, the first stack successively comprising: a first electrode, a first barrier layer made of an electrically insulating material, and a second electrode, the first electrode, the first barrier layer and the second electrode forming a first ferroelectric tunnel junction, at least one synapse comprising a second stack of superimposed layers, the second stack successively comprising: a third electrode, a second barrier layer made of an electrically insulating material, and a fourth electrode, the third electrode, the second barrier layer and the fourth electrode forming a second ferroelectric tunnel junction.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: January 10, 2023
    Assignees: UNIVERSITE PARIS-SACLAY, THALES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Manuel Bibes, Julie Grollier, Vincent Garcia, Nicolas Locatelli
  • Publication number: 20230000801
    Abstract: A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 5, 2023
    Applicants: CLEVEXEL PHARMA, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAY
    Inventors: Denis BRICOUT, Xiuping WANG-ZHANG, Eric DEUTSCH, Céline CLEMENSON